Phase 2, double-blind, randomized, placebo-controlled study of the safety and efficacy of elagolix in women with polycystic ovary syndrome

February 2023 in “ F&S Reports ”

Michael C. Snabes, Juki Ng, Hong Li, Izna Ali, Mohamad Shebley, William D. Schlaff

We don't know much about this study yet.

We're maintaining the world's largest resposity of hair loss research. You can help out the community by sending a PDF of this study here . Not sure how to get a study's PDF? You can email the authors of the study.

View this study on fertstertreports.org →

Discuss this study in the Community →

Research cited in this study

2 / 2 results

The Prevalence of Polycystic Ovary Syndrome in a Normal Population According to the Rotterdam Criteria Versus Revised Criteria Including Anti-Mullerian Hormone

research The Prevalence of Polycystic Ovary Syndrome in a Normal Population According to the Rotterdam Criteria Versus Revised Criteria Including Anti-Mullerian Hormone

221 citations , January 2014 in “Human Reproduction”

Adding anti-Müllerian hormone to PCOS criteria lowers the number of women diagnosed.

research The Androgen Excess and PCOS Society Criteria for the Polycystic Ovary Syndrome: The Complete Task Force Report

1540 citations , October 2008 in “Fertility and Sterility”

The report concludes that PCOS is mainly a condition of excess male hormones and its definition may change as new information is discovered.